Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vanguard Therapeutics

Vanguard Therapeutics
2009 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
3 INVESTORS
Description

Developer of therapy for sickle cell disease that targets the process that drives sickle cell disease -- abnormal blood flow. The company's oral drug that blocks the cell adhesion molecule P-selectin addresses the problem of sickle red blood cells sticking to the vascular endothelium, helping to improve blood flow, mitigate acute painful crises, and improve the quality of life of patients with sickle cell disease.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
  • 108 Eagle Trace Drive
  • Half Moon Bay, CA 94019
  • United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vanguard Therapeutics’s full profile, request a free trial.

Vanguard Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 01-Jan-2015 Completed Startup
3. Grant 15-Feb-2014 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator 01-Apr-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Vanguard Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BayBio FAST Accelerator/Incubator 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Vanguard Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Stephen Embury MD Founder, Chief Executive Officer & Chairman